TR GREEN ( 81-GN-5 )

CMX2000-81 TEAL PLASTISOL

NEU-100I MAMMOTH/LP/CX02-81

Geon(TM) SP107-81 Acoustical Barrier - Gry

Geon(TM) V4085-81 Grey Plastisol

J-WHITE 81

SD 6101-81

Geon(TM) FK150-81 Gray Foam NP

Microsoft PowerPoint - AVNT Q2 2021 Earnings Presentation - Website AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 1 R E S U LT S (NYSE: AVNT) J U LY 3 0 , 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 23 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 2 2 2 3 3 3 4 3 4 4 5 5 5 5 5 6 7 27 e nt e nt ( xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 en t (6) Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.

Microsoft PowerPoint - Avient Q4 Earnings and 2021 Outlook PRINT AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 0 R E S U L T S A N D 2 0 2 1 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 9 , 2 0 2 1 DISCLAIMER Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Other 2 3 2 2 2 3 3 3 4 4 5 5 5 6 6 6 7 9 25 t (E xc l. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.